🔗 Share this article

While the US proceeds with unprecedented changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by questioning coronavirus vaccines in the pandemic and has focused upon potential deaths after Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Program

Health officials were set to announce major revisions to the childhood vaccination calendar recently, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of alignment with a large portion of the world with insufficient data for public health gain. This reveal has been pushed back until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US to become more similar to Denmark's approach, a country with nationalized medicine and a citizenry roughly the size of Wisconsin’s.

In her initial comments, she has kept her attention on immunizations – typically the purview of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, oversight or leadership, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in managing a major agency. She lacks background in industry regulation.”

Previous heads of the center would “understand regulatory frameworks and the underlying principles of drug development”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who headed the center have had.”

The drug center has an enormous portfolio at the FDA, Woodcock stated.

“Everybody just focuses on the innovative therapies, but the off-patent medication office authorizes thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and more, and each of these need to be looked after,” Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant management component to the position, which manages more than 5,000 employees. “It is a huge management job, if you do it right,” she concluded.

Response and Contentious Policies

In response to questions about Høeg’s qualifications and whether this appointment indicates greater collaboration among FDA leaders on vaccines, a representative stated that the “concerns stem from inaccurate assumptions”.

“Her experience aligns with the duties of her role,” the representative explained, noting the months Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched priority voucher program, a controversial one-day therapy clearance system that reportedly concerned her preceding directors. “By what process are these therapies being picked for this voucher program? Who takes the calls?” Howard said. “There is a lot of secrecy occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent rules of most medications, aside from vaccines.”

Public History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, past, Howard have noted. She published a research paper using unconfirmed public submissions to determine the incidence of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership featured altering rules for new vaccines and discontinuing “non-essential” vaccines, she remarked post-election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who commences with her beliefs and works backwards to retrofit the science in a very disingenuous, dishonest manner,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|